These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38606933)

  • 81. Metastatic prostate cancer in a transgenic mouse.
    Gingrich JR; Barrios RJ; Morton RA; Boyce BF; DeMayo FJ; Finegold MJ; Angelopoulou R; Rosen JM; Greenberg NM
    Cancer Res; 1996 Sep; 56(18):4096-102. PubMed ID: 8797572
    [TBL] [Abstract][Full Text] [Related]  

  • 82. In Vivo Selection of Intermediately- and Highly-Malignant Variants of Triple-negative Breast Cancer in Orthotopic Nude Mouse Models.
    Yano S; Takehara K; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM
    Anticancer Res; 2016 Dec; 36(12):6273-6277. PubMed ID: 27919946
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Benzyl Isothiocyanate Inhibits Prostate Cancer Development in the Transgenic Adenocarcinoma Mouse Prostate (TRAMP) Model, Which Is Associated with the Induction of Cell Cycle G1 Arrest.
    Cho HJ; Lim DY; Kwon GT; Kim JH; Huang Z; Song H; Oh YS; Kang YH; Lee KW; Dong Z; Park JH
    Int J Mol Sci; 2016 Feb; 17(2):264. PubMed ID: 26907265
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer.
    Cheng S; Prieto-Dominguez N; Yang S; Connelly ZM; StPierre S; Rushing B; Watkins A; Shi L; Lakey M; Baiamonte LB; Fazili T; Lurie A; Corey E; Shi R; Yeh Y; Yu X
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):661-669. PubMed ID: 32313141
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Animal models of bone metastasis.
    Rosol TJ; Tannehill-Gregg SH; LeRoy BE; Mandl S; Contag CH
    Cancer; 2003 Feb; 97(3 Suppl):748-57. PubMed ID: 12548572
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease.
    Kang BH; Tavecchio M; Goel HL; Hsieh CC; Garlick DS; Raskett CM; Lian JB; Stein GS; Languino LR; Altieri DC
    Br J Cancer; 2011 Feb; 104(4):629-34. PubMed ID: 21285984
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy.
    Erstad DJ; Sojoodi M; Taylor MS; Ghoshal S; Razavi AA; Graham-O'Regan KA; Bardeesy N; Ferrone CR; Lanuti M; Caravan P; Tanabe KK; Fuchs BC
    Dis Model Mech; 2018 Jul; 11(7):. PubMed ID: 29903803
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse model.
    Kovar JL; Johnson MA; Volcheck WM; Chen J; Simpson MA
    Am J Pathol; 2006 Oct; 169(4):1415-26. PubMed ID: 17003496
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
    Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
    J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
    [TBL] [Abstract][Full Text] [Related]  

  • 90. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis.
    Wong SY; Haack H; Crowley D; Barry M; Bronson RT; Hynes RO
    Cancer Res; 2005 Nov; 65(21):9789-98. PubMed ID: 16267000
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Characterization of tumor-associated macrophages in prostate cancer transgenic mouse models.
    de Groot AE; Myers KV; Krueger TEG; Kiemen AL; Nagy NH; Brame A; Torres VE; Zhang Z; Trabzonlu L; Brennen WN; Wirtz D; De Marzo AM; Amend SR; Pienta KJ
    Prostate; 2021 Jul; 81(10):629-647. PubMed ID: 33949714
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
    Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM
    Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823
    [TBL] [Abstract][Full Text] [Related]  

  • 94. High-resolution ultrasound allows percutaneous initiation and surveillance of prostate cancer in an orthotopic murine model.
    Körbel C; Jung V; Kamradt J; Stöckle M; Unteregger G; Menger MD; Saar M
    Urol Int; 2015; 94(3):347-53. PubMed ID: 25115765
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Differential effects of omega-3 PUFAS on tumor progression at early and advanced stages in TRAMP mice.
    Amaro GM; da Silva ADT; Tamarindo GH; Lamas CA; Taboga SR; Cagnon VHA; Góes RM
    Prostate; 2022 Dec; 82(16):1491-1504. PubMed ID: 36039485
    [TBL] [Abstract][Full Text] [Related]  

  • 96. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
    Kim J; Jin H; Zhao JC; Yang YA; Li Y; Yang X; Dong X; Yu J
    Oncogene; 2017 Jul; 36(28):4072-4080. PubMed ID: 28319070
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The relationship of neuroendocrine carcinomas to anti-tumor therapies in TRAMP mice.
    Tang Y; Wang L; Goloubeva O; Khan MA; Lee D; Hussain A
    Prostate; 2009 Dec; 69(16):1763-73. PubMed ID: 19691128
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Early growth inhibition is followed by increased metastatic disease with vitamin D (calcitriol) treatment in the TRAMP model of prostate cancer.
    Ajibade AA; Kirk JS; Karasik E; Gillard B; Moser MT; Johnson CS; Trump DL; Foster BA
    PLoS One; 2014; 9(2):e89555. PubMed ID: 24586868
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Overexpression of 12/15-lipoxygenase, an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice.
    Kelavkar UP; Glasgow W; Olson SJ; Foster BA; Shappell SB
    Neoplasia; 2004; 6(6):821-30. PubMed ID: 15720809
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
    Wang J; Xu W; Mierxiati A; Huang Y; Wei Y; Lin G; Dai B; Freedland SJ; Qin X; Zhu Y; Ye DW
    Prostate; 2019 Sep; 79(13):1563-1571. PubMed ID: 31376193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.